Drug intelligence / Profile preview

MVP005

Development stage: Phase 1
Lead developer: Mitovie Pharma
Modality: Small Molecules
Administration: Intranasal

Overview

MVP005 is an intranasal spray formulation of naloxone, a small molecule opioid antagonist. Developed by Mitovie Pharma Ltd, it is being investigated in a Phase I clinical trial to compare its pharmacokinetics, safety, and tolerability against an intranasal administration of naloxone solution for injection in healthy adult subjects. Naloxone is primarily used to rapidly reverse the effects of opioid overdose.

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on MVP005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MVP005.

Explore the full profile